Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Artemisinin Stories

2014-01-22 11:47:15

‘Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine’ concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM. Dihydroartemisinin-piperaquine is one of five artemisinin-based combination therapies currently recommended by the World Health Organization (WHO), and this review finds that it is also one of the most studied. The team of authors from South Africa, Kenya,...

2013-12-11 23:03:56

Despite gains, recent financial shortfalls and delays in the delivery of commodities have slowed progress, demonstrating the fragility of past success, according to findings of the World Health Organization’s World Malaria Report 2013. New York, NY (PRWEB) December 11, 2013 The World Health Organization’s World Malaria Report 2013, released today, notes continued progress to significantly reduce malaria cases and deaths. But the report also documents that financial shortfalls in 2011...

2013-12-04 10:38:28

An analysis of patients from across the malaria endemic world suggests that a key antimalarial treatment could be improved by better dosing in young children Antimalarial drug resistance has hampered malaria control programs for almost 60 years. A key factor in combatting this threat is to ensure that all antimalarial drugs are deployed in a way that ensures that the maximum number of patients are completely cured. A study published this week in PLOS Medicine explores this issue by...

2013-10-30 10:48:05

The first dynamic regulatory system that prevents the build-up of toxic metabolites in engineered microbes has been reported by a team of researchers with the U.S. Department of Energy (DOE)’s Joint BioEnergy Institute (JBEI). The JBEI researchers used their system to double the production in Escherichia coli (E. coli) of amorphadiene, a precursor to the premier antimalarial drug artemisinin. Using genome-wide transcriptional analysis, the JBEI researchers identified native regions of...

2013-09-13 16:24:50

ST. LOUIS, Sept. 13, 2013 /PRNewswire-USNewswire/ -- Saint Louis University's Center for World Health and Medicine has received a three-year $566,640 grant from the National Institutes of Health to study a new approach to treating malaria, a disease that puts about one billion people at risk worldwide, killing approximately one million annually. The project investigates the potential of novel classes of antimalarial drugs to treat drug-resistant parasites that cause malaria and...

2013-06-18 12:30:30

Senator Dan Coats, Congressman Ander Crenshaw, Congressman Gregory Meeks and Novartis honored at Malaria Champions Breakfast WASHINGTON, June 18, 2013 /PRNewswire-USNewswire/ -- Malaria No More today announced the recipients of annual awards for distinguished service in the fight against malaria. The three separate awards, which this year are being received by Senator Dan Coats (R-IN), Congressmen Ander Crenshaw (R-04-FL) and Gregory Meeks (D- -NY), and Novartis were presented this...

2013-05-15 23:27:23

Chinese malaria drugs giant, Guilin, launches effort in Africa to enable patients and consumers detect fake malaria drugs using mobile phone technology, goldkeys. Shanghai, China (PRWEB) May 15, 2013 Guilin Pharmaceuticals, the World´s first producer of artesunate prequalified by the World Health Organisation as meeting the global body´s stringent standards for safety, quality and efficacy, has chalked another first. The company, which manages the world´s largest vertically...

2013-04-25 12:27:39

-- Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria BASEL, Switzerland, April 25, 2013 /PRNewswire/ -- Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will support the...

Large-scale Production Of Partially Synthetic Version Of Artemisinin Launched
2013-04-11 15:19:17

University of California - Berkeley Twelve years after a breakthrough discovery in his University of California, Berkeley, laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true. On April 11, the pharmaceutical company Sanofi will launch the large-scale production of a partially synthetic version of artemisinin, a chemical critical to making today's front-line antimalaria drug, based on Keasling's discovery. The drug is the first triumph of the...

2013-03-08 16:22:21

VANCOUVER, British Columbia, March 8, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), is pleased to announce its participation in a research project led by Pamela Weathers, Professor of Biology and Biotechnology at Worcester Polytechnic Institute (WPI) in Worcester, Mass. that is investigating a whole plant therapeutic for treating malaria and other diseases, one that may also reduce drug resistance. Mr. Mike Withrow, Chief Executive...